First Time Loading...

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 1.075 USD 1.42% Market Closed
Updated: Apr 29, 2024

Adaptimmune Therapeutics PLC
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptimmune Therapeutics PLC
Cash from Operating Activities Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Cash from Operating Activities
-$140.9m
CAGR 3-Years
-38%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$160.3m
CAGR 3-Years
-147%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash from Operating Activities
-$145.6m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Operating Activities
-$60.6m
CAGR 3-Years
-50%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
£2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
£44.6m
CAGR 3-Years
-16%
CAGR 5-Years
4%
CAGR 10-Years
3%

See Also

What is Adaptimmune Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-140.9m USD

Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Cash from Operating Activities amounts to -140.9m USD.

What is Adaptimmune Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-6%

Over the last year, the Cash from Operating Activities growth was 1%. The average annual Cash from Operating Activities growth rates for Adaptimmune Therapeutics PLC have been -38% over the past three years , -6% over the past five years .